Zusammenfassung
Grundlagen: Nach derzeitigem Stand der Forschung gilt ein Duodeno-Gastro-Ösophagealer Reflux
(DGER) als unabhängiger Risikofaktor sowohl für die Entstehung einer Refluxösophagitis
als auch für die Ausbildung einer Barrett-Metaplasie der Speiseröhre. Mit der Bilitec-2000-Untersuchung
ist es mittlerweile möglich, das Ausmaß eines DGER quantitativ zu bestimmen. Daten
über die Prävalenz eines pathologischen DGER stehen ebenso wenig zur Verfügung wie
eine leitliniengerechte Therapie. Methoden: 146 Patienten mit klinischen Beschwerden einer Refluxerkrankung wurden in die Untersuchung
eingeschlossen. Alle Patienten erhielten neben der Standarddiagnostik bestehend aus
der Abfrage klinischer Symptome mittels Fragebogen, Gastroskopie, 24h-pH-Metrie und
Ösophagusmanometrie eine quantitative Messung des DGER. Ergebnisse: Von 146 Patienten wiesen 74 (51 %, 39 Männer, 34 Frauen) einen pathologischen DGER
auf. Hiervon zeigten 28 Patienten einen isolierten DGER (19 %), 46 Patienten einen
kombinierten Reflux (DGER und Magensäurereflux) (32 %). Ein isolierter Magensäurereflux
konnte bei weiteren 28 Patienten (19 %) diagnostiziert werden. Das quantitative Ausmaß
eines DGER korrelierte mit dem Nachweis einer komplizierten Refluxerkrankung mit endoskopischen
Zeichen einer Refluxösophagitis oder einer Barrett-Schleimhaut. Schlussfolgerung: 1. Patienten mit den klinischen Beschwerden einer GERD weisen eine hohe Prävalenz
eines pathologischen DGER auf. 2. Der kombinierte Einsatz einer 24h-pH-Metrie und
der Bilitec-Untersuchung verbessert die diagnostische Genauigkeit bei der Abklärung
einer GERD. 3. Analog dem sauren Reflux nimmt der DGER mit der Schwere der Schleimhautläsionen
der Speiseröhre zu.
Abstract
Background: According to recent studies DGER (duodeno-gastric-oesophageal reflux) is considered
as an independent risk factor for the development of reflux esophagitis and the Barrett
metaplasia. The Bilitec 2000 allows a qualitative and quantitative measurement of
DGER in patients with symptoms of reflux disease. The aim of the present study was
to investigate the prevalence of DGER in patients with reflux symptoms. Methods: 146 patients with symptoms of gastro-oesophageal reflux disease were enrolled in
this study. Patients underwent upper gastrointestinal endoscopy, oesophageal manometry
and simultaneous 24 h oesophageal pH and bilirubin monitoring. The presence of pathological
DGER and its relations to the symptom pattern, distal oesophageal acid exposure and
endoscopic findings were analysed. Results: In 74 out of 146 patients (51 %, 39 men, 34 women) a DGER could be detected. Twenty-eight
(32 %) of these patients suffered from an isolated DGER, while 46 (32 %) had a combined
acid and DGER reflux. An isolated acid reflux was found in additional 28 (19 %) patients.
The degrees of both acid and DGER were significantly higher in those patients with
oesophageal lesions. Conclusions: 1. There is a high prevalence of DGER in patients with the clinical symptoms of a
reflux disease. 2. The combined measurement of acid reflux and DGER helps to better
define the cause of reflux symptoms. 3. In analogy to the acid reflux DGER increases
with the gravity of oesophageal lesions.
Schlüsselwörter
Refluxösophagitis - Barrett-Metaplasie - GERD - Bilitec - DGERD
Key words
Refluxoesophagititis - Barrett-Oesophagus - GERD - Bilitec - DGERD
Literatur
1
Talley N J, Boyce P, Jones M.
Identification of distinct upper and lower gastrointestinal symptom groupings in an
urban population.
Gut.
1998;
42
690-695
2
Papatheodoridis G V, Karamanolis D G.
Prevalence and impact of upper and lower gastrointestinal symptoms in the Greek urban
general population.
Scand J Gastroenterol.
2005;
40
412-421
3
Furukawa N, Iwakiri R, Koyama T. et al .
Proportion of reflux esophagitis in 6010 Japanese adults: prospective evaluation by
endoscopy.
J Gastroenterol.
1999;
34
441-444
4
Miyamoto M, Haruma K, Kuwabara M. et al .
High incidence of newly-developed gastroesophageal reflux disease in the Japanese
community: A 6-year follow-up study.
J Gastroenterol Hepatol.
2007;
Jul 1 [epub ahead of print]
5
El-Serag H B, Sonnenberg A.
Opposing time trends of peptic ulcer and reflux disease.
Gut.
1998;
43 (3)
327-333
6
El-Serag H B, Sonnenberg A, Jamal M M. et al .
Corpus gastritis is protective against reflux oesophagitis.
Gut.
1999;
45 (2)
181-185
7
Armstrong D, Marshall J K, Chiba N. et al .
Canadian consensus conference on the management of gastroesophageal reflux disease
in adultsupdate 2004.
Can J Gastroenterol.
2005;
19
15-35
8
Locke III G R.
Natural history of nonerosive reflux disease, is all gastroesophageal reflux disease
the same, what is the evidence?.
Gastroenterol Clin N Am.
2002;
31
S59-S66
9
Ofman J J.
The economic and quality-of-life impact of symptomatic gastroesophageal reflux disease.
Am J Gastroenterol.
2003;
98 (Suppl)
S8-S14
10
Johanson J F, Siddique R, Damiano A M. et al .
Rabeprazole improves healthy-related quality of life in patients with erosive gastroesophageal
reflux disease.
Dig Dis Sci.
2002;
47
2574-2578
11 Kahrilas P J, Pandolfino J E. Gastroesophageal reflux disease and its complications,
including Barrett’s metaplasia. Feldman M, Friedman LS, Sleisenger MH Gastrointestinal
and liver disease Philadelphia, London, New York, St. Louis, Sydney, Toronto; Saunders
2002 7th edn: 599-622
12
Hirsch D P, Tytgat G NJ, Boeckxstaens G EE.
Review article: transient lower oesophageal sphincter relaxations - a pharmacological
target for gastro-oesophageal reflux disease.
Aliment Pharmacol Ther.
2002;
16
17-26
13
Meining A, Classen M.
The role of diet and lifestyle measures in the pathogenesis and treatment of gastroesophageal
reflux disease.
Am J Gastroenterol.
2000;
95 (10)
2692-2697. Review
14
Lundell L, Dent J, Bennett J. et al .
Endoscopic assessment of oesophagitis: clinical and functional correlates and further
validation of the Los Angeles classification.
Gut.
1999;
45
172-180
15
Hirota W K, Loughney T M, Lazas D J. et al .
Specialized intestinal metaplasia,dysplasia,and cancer of the esophagus and esophagogastric
junction: prevalence and clinical data.
astroenterology.
1999;
116
277-285
16
Atherfold P A, Jankowski J A.
Molecular biology of Barrett’s cancer.
Best Pract Res Clin Gastroenterol.
2006;
20 (5)
813-827
17
Vaezi M F, Richter J E.
Duodenogastroesophageal reflux and methods to monitor nonacidic reflux.
Am J Med.
2001;
111 (Suppl 8A)
160S-168S
18
Vaezi M F, Singh S, Richter J E.
Role of acid and duodenogastric reflux in esophageal mucosal injury: a review of animal
and human studies.
Gastroenterology.
1995;
108
1897-1907
19
Goldberg H I, Dodds W J, Gee S. et al .
Role of acid and pepsin in acute experimental esophagitis.
Gastroenterology.
1969;
56
223-230
20
Harmon J W, Johnson L F, Maydonovitch C L.
Effects of acid and bile salts on the rabbit esophageal mucosa.
Dig Dis Sci.
1981;
26
65-72
21
Lillemoe K D, Johnson L F, Harmon J W.
Role of the components of the gastroduodenal contents in experimental acid esophagitis.
Surgery.
1982;
92
276-284
22
Salo J A, Kivilaakso E.
Contribution of trypsin and cholate to the pathogenesis of experimental alkaline reflux
esophagitis.
Scand J Gastroenterol.
1984;
19
875-881
23
Johnson L F, Harmon J W.
Experimental esophagitis in a rabbit model. Clinical relevance.
J Clin Gastroenterol.
1986;
8 (Suppl 1)
26-44
24
Schweitzer E J, Bass B L, Batzri S. et al .
Bile acid accumulation by rabbit esophageal mucosa.
Dig Dis Sci.
1986;
31
1105-1113
25
Zhang F, Altorki N K, Wu Y C. et al .
Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence
for involvement of bile acids.
Gastroenterology.
2001;
121
1391-1399
26
Tselepis C, Morris C D, Wakelin D. et al .
Upregulation of the oncogene c-myc in Barrett’s adenocarcinoma: induction of c-myc
by acidified bile acid in vitro.
Gut.
2003;
52
174-180
27
Vaezi M F, Richter J E.
Synergism of acid and duodenogastroesophageal reflux in complicated Barrett’s esophagus.
Surgery.
1995;
117 (6)
699-704
28
Orlando R C, Bozymski E M.
Heartburn in pernicious anemia - a consequence of bile reflux.
N Engl J Med.
1973;
289
522-523
29
Wilmer A, Tack J, Frans E. et al .
Duodenogastroesophagealreflux and e sophageal mucosal injury in mechanically ventilated
patients.
Gastroenterology.
1999;
116
1239
30
Stipa F, Stein H J, Feussner H. et al .
Assessment of non-acidic esophageal reflux: comparison between long-term reflux aspiration
test and fiberoptic bilirubin monitoring.
Dis Esophagus.
1997;
10
24-28
31
Vaezi M F, Lacamera R G, Richter J E.
Validation studies of Bilitec 2000: an ambulatory duodenogastric reflux monitoring
system.
Am J Physiol.
1994;
267
G1050-G1057
32
Vaezi M F, Richter J E.
Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease.
Gastroenterology.
1996;
111
1192-1199
33
Miwa K, Sahara H, Segawa M. et al .
Reflux of duodenal or gastro-duodenal contents induces esophageal carcinoma in rats.
Int J Cancer.
1996;
67
269-274
34
Consensus conference of the DGVS on gastroesophageal reflux.
Z Gastroenterol.
2005;
43 (2)
163-164
35
Castell D O, Vela M.
Combined multichannel intraluminal impedance and pH-metry: an evolving technique to
measure type and proximal extent of gastroesophageal reflux.
Am J Med.
2001;
111 (Suppl 8A)
157S-159S. Review
36
Tutuian R, Castell D O.
Multichannel intraluminal impedance: general principles and technical issues.
Gastrointest Endosc Clin N Am.
2005;
15 (2)
257-264. Review
37
Weigt J, Mönkemüller K, Kolfenbach S. et al .
Standards and innovations in the diagnosis of gastroesophageal reflux disease.
Z Gastroenterol.
2007;
45 (11)
1141-1149
38
Roman S, Poncet G, Serraj I. et al .
Characterization of reflux events after fundoplication using combined impedance-pH
recording.
Br J Surg.
2007;
94 (1)
48-52
39
Vela M F, Tutuian R, Katz P O. et al .
Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured
by combined multichannel intraluminal impedance and pH.
Aliment Pharmacol Ther.
2003;
17 (2)
243-251
40
Pace F, Sangaletti O, Pallotta S. et al .
Biliary reflux and non-acid reflux are two distinct phenomena: a comparison between
24-hour multichannel intraesophageal impedance and bilirubin monitoring.
Scand J Gastroenterol.
2007;
42 (9)
1031-1039
Dr. Steffen Kunsch
Universitätsklinikum Marburg
Baldingerstraße
35043 Marburg
Email: kunsch@med.uni-marburg.de